Business Context and Reporting Period
Company: Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Mirum is a biopharmaceutical company focused on rare diseases, specifically cholestatic liver diseases and Fragile X Syndrome. The company commercializes three approved medicines: Livmarli (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC); Cholbam (cholic acid) for bile acid synthesis disorders; and Chenodal/Ctexli (chenodiol) for cerebrotendinous xanthomatosis (CTX). The company also has a pipeline including volixibat (for PSC and PBC) and MRM-3379 (for Fragile X Syndrome).
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 |
|---|---|---|
| Total Revenue | $336.9 | $186.4 |
| Product Sales, Net | $336.4 | $178.9 |
| Net Loss | $(87.9) | $(163.4) |
| Operating Loss | $(87.6) | $(109.2) |
| Research & Development Expenses | $140.6 | $102.6 |
| Selling, General & Administrative Expenses | $202.2 | $145.9 |
| Cash, Cash Equivalents & Investments | $293.3 | $286.3 |
| Convertible Notes Payable (Principal) | $316.3 | $316.3 |
Note: 2023 Net Loss included a $49.1 million loss from the termination of a revenue interest purchase agreement (RIPA).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 81% ($150.5 million) year-over-year. Product sales grew 88% to $336.4 million, driven by the full-year contribution of the Bile Acid Medicines (Cholbam and Chenodal) following the August 2023 acquisition of Travere Therapeutics assets, and continued growth in Livmarli sales.
- Improved Net Loss: Net loss decreased by 46% to $87.9 million, primarily due to the absence of the $49.1 million RIPA termination loss recorded in 2023 and increased revenue.
- Expense Increases: Operating expenses rose significantly. R&D expenses increased $38.0 million due to clinical trial costs for volixibat and the $7.5 million upfront payment for the MRM-3379 license. SG&A expenses increased $56.3 million due to expanded commercial teams and marketing efforts.
- Regulatory Milestones: In February 2025 (post-period), the FDA approved chenodiol for the treatment of adults with CTX, to be commercialized as Ctexli. In October 2024, the FDA granted Breakthrough Therapy Designation for volixibat for cholestatic pruritus in PBC.
Guidance, Outlook, and Risks
Outlook and Guidance:
- The company expects to continue generating net losses for the foreseeable future as it funds clinical development and commercialization.
- Management anticipates total product sales will continue to increase annually.
- Cash resources of $293.3 million are deemed sufficient to fund operations for at least the next 12 months.
- Convertible Notes: The 4.00% Convertible Senior Notes due 2029 ($316.3 million principal) became convertible at the option of holders during the first quarter of 2025 due to stock price performance in Q4 2024.
Key Risks and Contingencies:
- Profitability: The company has an accumulated deficit of $644.2 million and relies on future financing or revenue growth to achieve profitability.
- Competition: Significant competition exists in cholestatic liver diseases, including Ipsen's odevixibat (Bylvay/Kayfanda) and GSK's linerixibat (expected approval in H2 2025).
- Intellectual Property: The company lacks patent protection for the composition of matter for chenodiol and Cholbam, relying on regulatory exclusivity and method-of-use patents for Livmarli.
- Supply Chain: Reliance on third-party manufacturers and a single specialty pharmacy for U.S. and Canadian sales creates operational risks.
Investor Verification Checklist
- Convertible Note Conversion: Verify the extent of potential dilution or cash outflow if holders convert the $316.3 million in notes in Q1 2025.
- Ctexli Commercialization: Assess the launch strategy and market acceptance for Ctexli (chenodiol) following its February 2025 FDA approval for CTX.
- Volixibat Trial Progress: Monitor enrollment and interim data for the VISTAS (PSC) and VANTAGE (PBC) Phase 2b trials, with enrollment completion expected in H2 2025 and 2026, respectively.
- Patent Landscape: Review the competitive threat from GSK's linerixibat and Ipsen's odevixibat, which may impact Livmarli and volixibat market share.
- Liquidity Runway: Confirm that the $293.3 million cash balance remains sufficient given the high burn rate associated with clinical trials and commercial expansion.